
City-based firm gets DGCI nod for phase 2 drug trials
The Hindu
Council of Scientific & Industrial Research (CSIR), and city-based Laxai Life Sciences have been given the regulatory approval by Drugs Controller General of India (DGCI) to undertake a two-ar
Council of Scientific & Industrial Research (CSIR), and city-based Laxai Life Sciences have been given the regulatory approval by Drugs Controller General of India (DGCI) to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients. CSIR institutes in this important clinical trial are the Indian Institute of Chemical Technology (IICT) in Hyderabad and Indian Institute of Integrative Medicine (IIIM) at Jammu. “CSIR’s two partner institutes are looking forward to the outcome of this phase II clinical efficacy trial on Colchicine, which may lead to life-saving intervention in the management of hospitalised patients. India is one of the largest producers of this key drug and if successful, it will be made available to the patients at an affordable cost,” said IICT director S. Chandrasekhar and IIIM director DS Reddy in a joint statement.More Related News













